MAPK14 and rheumatoid arthritis: Compound 70 (CAS 449811-92-1), patented by Hoffmann-La Roche (R-1487) in 2002 [116] for the treatment of p38 mediated disorders, was investigated for use/treatment in rheumatoid arthritis but was discontinued in 2004.